계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Salmedix
company
About
It focuses on the treatment of hematologic malignancies or blood cancers.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $27.50M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Nov 1, 2000
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers.Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development.Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$27.50M
Salmedix has raised a total of
$27.50M
in funding over 2 rounds. Their latest funding was raised on
Jun 19, 2002 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 19, 2002 | Series B | $27.50M | 2 | — | — | Detail |
| Jan 1, 2001 | Series A | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Salmedix is funded by 2 investors.
Biofrontier Partners
and Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Biofrontier Partners
|
— | Series B |
Versant Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
